Customized treatment for infants with newly diagnosed leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a treatment plan that adjusts therapy based on each baby's risk level. It aims to improve outcomes for infants newly diagnosed with certain types of leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be less than 1 year old at diagnosis
- Diagnosis must be ALL (acute lymphoblastic leukemia) or ALAL with mainly lymphoid features
- You (the parent or guardian) must agree to the study and sign a consent form
- The leukemia must be newly diagnosed, not a relapse
- Your baby cannot have certain genetic conditions like Down syndrome or bone marrow failure syndromes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This trial tests a new treatment approach for children and teens with high-risk acute lymphoblastic leukemia (ALL). It aims to improve outcomes for those with certain genetic changes or cancer that has spread.
This trial tests a new treatment plan for children with very high-risk acute lymphoblastic leukemia. It aims to improve outcomes for patients whose leukemia has specific genetic markers or has not responded well to initial treatment.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
This early-phase study is testing a “total therapy” treatment plan for very young babies (diagnosed within the first year of life) with certain types of leukemia that carry the CD19 marker. It may help find safer and more effective treatment for infants with this disease, especially soon after diagnosis.
Hear when a new Leukemia, Lymphoid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.